ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Two biotech companies developing compounds brought in from larger firms are attempting to go public. Biohaven Pharmaceutical aims to raise $100 million in an initial public offering. The funds will support Phase III studies of rimegepant, a migraine treatment licensed from Bristol-Myers Squibb, and earlier-stage studies of compounds for spinocerebellar ataxia and Rett syndrome. Meanwhile, Ovid Therapeutics hopes its IPO will bring in $86 million to fund R&D, including several studies of OV101, a rare-disease drug licensed from Lundbeck.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X